Background and purpose: Cerebrospinal fluid (CSF) tau and neurofilament light chain (NF-L) proteins have proved to be reliable biomarkers for neuronal damage; however, there is a strong need for blood-based tests. Methods: The present study included 132 autopsy cases with rapidly progressive neurological syndromes, including Alzheimer disease (AD) (21), sporadic (65) and genetic (21) Creutzfeldt-Jakob disease (CJD), 25 cases with vascular, neoplastic and inflammatory alterations, and additionally 18 healthy control individuals. CSF tau and NF-L concentrations were measured by enzymelinked immunosorbent assay. Plasma tau and NF-L concentrations were measured using ultra-sensitive single molecule array technology. Results: Plasma and CSF tau (R = 0.59, P < 0.001) and NF-L (R = 0.69, P < 0.001) levels correlated significantly (Spearman test). Plasma tau and NF-L levels were significantly higher in all disease groups compared to healthy controls (P < 0.001). Receiver operating characteristic curves were used and area under the curve values for comparisons with controls were 0.82 (AD), 0.94 (sporadic CJD), 0.92 (genetic CJD) and 0.83 (other neurological disorders) for plasma tau and 0.99, 0.99, 1.00 and 0.96 for plasma NF-L, respectively. Molecular subtyping of sporadic CJD showed a strong effect (linear logistic regression) on plasma tau (P < 0.001) but not NF-L levels (P = 0.19). Conclusion: Plasma tau and NF-L concentrations are strongly increased in CJD and show similar diagnostic performance to the corresponding CSF measure. Molecular subtypes of sporadic CJD show different levels of plasma tau. Although not disease-specific, these findings support the use of plasma tau and NF-L as tools to identify, or to rule out, neurodegeneration.
Introduction
Neurodegenerative diseases are characterized by progressive degeneration and loss of neurons together with deposition of pathological forms of proteins predominantly in the central nervous system. Current molecular pathological classification of neurodegenerative disease is therefore protein-based [1] . The most important proteins such as tau, a-synuclein, transactive response (TAR) DNA-binding protein , amyloid-b (Ab) and prion protein (PrP) are targets for body-fluid-based biomarker development [1] . In the diseased brain these proteins show several biochemical modifications [1] ; therefore either the physiological or the modified forms are selected for in vivo tests. Although markers detecting total and pathological forms of a-synuclein [2] or disease-associated PrP [3, 4] are emerging, the currently most widely applied tests focusing on neurodegeneration-associated proteins are used for supporting the clinical diagnosis of Alzheimer disease (AD). These include the examination of total and phosphorylated (p181) tau (p-tau) and Ab levels and have relevance in the context of diagnosing AD both in the dementia and prodromal stages of the disease [5] and also for defining preclinical AD [6] . Currently, these markers are analysed in cerebrospinal fluid (CSF) samples that require lumbar puncture. Since most patients are evaluated by primary care doctors, there is a strong need for blood-based tests [7] .
Biomarker modelling of AD emphasizes the importance of total tau as a marker of neurodegeneration [8] . Indeed, neurodegeneration-related proteins are important for disease classification even in the context of frequent concomitant pathologies [9] ; however, the relevance of biomarkers reflecting the dynamics of neuronal degeneration remains high. In particular, these may allow assessment of prognosis or response to potential therapeutic efforts. Total tau measured in CSF has proved to be a reliable marker of neuronal damage. Indeed, the most widely used biomarkers for the clinical diagnosis of the most frequent human prion disease sporadic Creutzfeldt-Jakob disease (CJD) include protein 14-3-3 and total tau [10, 11] , with the CSF p-tau/total tau ratio having a discriminative power of 0.98 for CJD against either AD or other dementias [12] . These biomarkers show altered levels in genetic CJD as well [10] . Furthermore, recent studies emphasize that there might be differences between molecular subtypes of sporadic CJD [13] . Molecular subtypes of sporadic CJD are distinguished based on the polymorphic codon 129 of the prion protein gene (PRNP) and types of protease-resistant PrP [14] . Detection of total PrP [15] and a-synuclein [16] has recently been added to the list of biomarkers helpful in the differential diagnosis of rapidly progressive dementias.
A further, potentially relevant biomarker of neuronal damage is neurofilament light chain (NF-L). This was reported already in 1996 to be increased in several neurodegenerative and non-neurodegenerative conditions [17] . Since NF-L is expressed in myelinated axons, studies have focused on multiple sclerosis [18] ; furthermore, increased levels have been reported in traumatic brain injury [19] . Importantly, recent studies suggest that NF-L can be reliably evaluated in serum samples and can reflect disease intensity in brain disorders [20] [21] [22] . Other studies have shown that total tau levels can also be measured in plasma [23] , although on an individual level tau concentrations in blood are not helpful, e.g. in the diagnostics of AD [24] .
Based on the aforementioned studies, it was hypothesized that the measurement of plasma tau and NF-L concentrations can be useful to support the diagnosis of human prion diseases. Therefore, a cohort of neuropathologically classified CJD cases was evaluated and compared with non-diseased controls and with a range of disorders defined by neuropathological examinations. Our study supports the concept that tau and NF-L concentrations can be reliably measured in plasma and that they probably reflect ongoing neuronal damage. They show similar diagnostic performance to their corresponding CSF measure but are not disease-specific.
Materials and methods

Case selection and samples
The present study included 132 autopsy cases of neuropathologically confirmed AD (21 cases), sporadic CJD (65 cases), genetic CJD (21 cases with the E200K PRNP mutation) and 25 cases with a wide range of neuropathological alterations, including cerebrovascular disease, inflammation (meningoencephalitis), primary age-related tauopathy, non-AD tauopathies or Lewy body pathology (Tables 1 and S1 ). Lewy body pathology [25] and neurofibrillary degeneration [26, 27] were staged for all cases (Table 1) . Tauopathies included argyrophilic grain disease or progressive supranuclear palsy type pathology [28] . Molecular subtypes of sporadic CJD were defined following the classification by Parchi et al. [14, 29] . Further neurodegenerative disorders and proteinopathies were excluded [30] . The 18 normal controls were healthy volunteers and had no subjective symptoms of cognitive dysfunction; they were normal upon clinical, neurological and psychiatric examination. The sample collection of controls was approved by the ethical committee of Gothenburg University, and informed consent was obtained from all participants.
For all the neuropathologically examined patients, CSF samples had previously been submitted for routine analysis of 14-3-3 protein (in the frame of surveillance for prion diseases), together with plasma samples prepared from blood sent in EDTA tubes. The samples were taken on the same day. The reason for the request for 14-3-3 examinations was in all cases rapidly progressive cognitive decline or progressive neurological symptoms where the clinical suspicion of prion disease was raised. For the study only samples remaining after the diagnostic testing were used and the study did not involve a specific intervention for research. From the neuropathology cohort 132 plasma and 111 CSF samples were available. These were stored at À80°C. This allowed the investigation of CSF in combination with autopsy material from the same patient. The study was approved by the ethics committee of the Medical University of Vienna (no. 397/2011).
Analysis of tau and neurofilament in CSF and plasma samples
Cerebrospinal fluid levels of total tau protein were measured using the INNOTEST enzyme-linked immunosorbent assay (ELISA) (Fujirebio Europe, Ghent, Belgium), whilst NF-L levels were measured by the NF-lightÒ ELISA kit (UmanDiagnostics AB, Umea, Sweden). Plasma tau was measured using the Human Total Tau Kit (Quanterix, Lexington, MA, USA) on the Simoa HD-1 Analyzer (CE marker). This assay differs from the previously published Simoa tau assay [31] in that it is based on different antibodies: one monoclonal antibody for capture that binds to a linear epitope in the mid-region of tau, and one detection antibody that binds to a linear epitope in the N-terminal region of total tau. NF-L concentrations in blood were measured using the same monoclonal antibodies and calibrator as in the CSF assay, but the assay was transferred onto the Simoa platform 
AD, Alzheimer disease; sCJD and gCJD, sporadic and genetic Creutzfeldt-Jakob disease; OND, other neurological disorders; Co, clinically healthy controls; NFT, neurofibrillary tangle; LRP, Lewy-related pathology; Molpath, molecular pathological subtype; -, not applicable.
a Tauopathy indicates non-AD type tau pathologies. Table 1 Demographic and neuropathological data of the examined cases using a homebrew kit (Quanterix), as previously described [32] . All CSF and plasma measurements were performed by board-certified laboratory technicians who were blinded to clinical data.
Statistical analysis
The KruskalÀWallis (K-W) and MannÀWhitney (M-W) tests were used to compare different study groups. Linear logistic regression tests were performed to evaluate the effect of clinicopathological variables. Receiver operating characteristic (ROC) curves were used to evaluate the specificity and sensitivity of the tests used. For statistical analyses, SPSS Statistics were used (V23.0, SPSS Inc., Chicago, IL, USA).
Results
Plasma tau and NF-L levels correlate well with CSF tau and NF-L levels
The concentrations measured were at the picograms per milliliter level. CSF tau levels were higher than plasma tau levels (CSF/plasma tau, mean 779.1, range 11.39-10 076.9) and CSF NF-L was higher than plasma NF-L (CSF/plasma NF-L, mean 61.74, range 8.08-192.1). For the total cohort where both CSF and plasma samples were available (n = 93) a Spearman test revealed a correlation between plasma and CSF tau (R = 0.59, P < 0.001) and between CSF and plasma NF-L (R = 0.69, P < 0.001). CSF tau levels correlated with CSF NF-L (R = 0.42, P < 0.001) and plasma tau levels with plasma NF-L (R = 0.50, P < 0.001). CSF tau correlated with plasma NF-L (R = 0.34, P = 0.001) but CSF NF-L levels did not correlate with plasma tau levels (R = 0.16, P = 0.12) ( Table 2) . Whether age, gender and time interval from sampling to death (i.e. autopsy cohort) had any effect on these variables was then evaluated. No difference was found between men and women (M-W test, P > 0.2 for all variables). The Spearman correlation test revealed a negative correlation between age and CSF NF-L levels in the autopsy cohort (n = 93, R = À0.22, P = 0.03). However, in a linear logistic regression model with diagnostic grouping and age added to the model this was not significant (P = 0.1). Indeed, when evaluated in disease groups, age correlated inversely with CSF NF-L levels only in the sporadic CJD group (n = 46, R = À0.32, P = 0.02). The time interval from sampling to death (i.e. the whole autopsy cohort pooled) weakly correlated negatively with CSF tau (R = À0.26, P = 0.01), plasma tau (R = À0.38, P < 0.001) and plasma NF-L levels (R = À0.18, P = 0.03). When diagnostic groups were evaluated separately, this time interval correlated negatively only in AD (plasma tau, R = À0.46, P = 0.03), sporadic CJD (plasma tau, R = À0.54, P < 0.001; CSF tau, R = À0.3, P = 0.04) and in genetic CJD (CSF tau, R = À0.57, P = 0.03). Braak neurofibrillary tangle (NFT) and Lewy-related pathology stages did not show any effect on these variables.
Elevated plasma and CSF tau levels characterize AD and CJD cases When evaluating plasma tau levels, the K-W test revealed significant differences between cases (P < 0.0001) (Fig. 1a) . High levels were observed in sporadic CJD, which were significantly (P < 0.001) higher compared to all other groups (M-W test) except genetic CJD. Indeed, the mean plasma tau level in sporadic CJD cases showed a more than 10-fold increase compared to healthy controls and was also prominently increased compared to other neurological diseases (2.46-fold increase) or AD (2.28-fold increase). Plasma tau levels did not distinguish genetic CJD cases from other neurological diseases (P = 0.08) but were significantly higher than in AD cases (P = 0.03). Importantly, all disease groups showed significantly higher levels than the healthy control group (P < 0.001). The mean plasma tau level in AD was 4.45-fold higher than in controls (Fig. 1a) . In the group of other neurological disorders increased concentrations were noted in single cases with either neoplastic, vascular or inflammatory disorders (Tables S1 and S2) .
Next the sensitivity and specificity of the plasma tau levels were evaluated using ROC curves and the area under the curve (AUC) ( Table S3) . Relevant AUC values (>0.8) were observed for the following (Fig. 1b) although the AUC was higher in comparisons with sporadic and genetic CJD (Table S3) .
Elevated plasma and CSF NF-L levels in various brain disorders
When evaluating plasma NF-L levels, the K-W test revealed significant differences between cases (P < 0.0001) (Fig. 1c) . All diseased groups showed higher levels than controls (other neurological disease 27-fold, AD 12-fold, sporadic CJD 8-fold and genetic CJD 7-fold increase of mean value). The highest levels were observed in a few cases of the group of other neurological diseases; these were the same as those showing the highest plasma tau levels. Indeed, these cases with severe brain damage showed 10-100 times higher values than the normal controls. The M-W test revealed significant differences only for the comparisons with healthy controls (i.e. versus other neurological disorders, AD, sporadic and genetic CJD; all P < 0.001).
Next the sensitivity and specificity of plasma NF-L levels were evaluated using ROC curves (Table S3) When evaluating CSF NF-L levels for the autopsy cohort, similar trends were observed (Fig. 1d) . However, here further comparisons (M-W test) were significant as follows: (i) sporadic versus genetic CJD (P = 0.041); (ii) sporadic CJD versus AD (P = 0.002); (iii) genetic CJD versus AD (P < 0.001); and (iv) other neurological disorders versus AD (P = 0.036). The AUC (ROC curve) was below 0.8, except for the comparison of sporadic CJD and AD (0.86; 95% CI 0.71-1.0) ( Table S3 ).
The effect of molecular subtyping on tau and NF-L levels in sporadic CJD cases
The linear logistic regression test indicated that molecular subtypes of sporadic CJD have a strong effect on the plasma (P = 0.001) but not on the CSF (P = 0.3) tau levels, the first remaining significant (P = 0.002) after the adjustment for Braak NFT stage and the time interval between sampling and death. Regarding plasma NF-L levels, molecular subtyping of sporadic CJD did not show a significant effect (P = 0.19).
Plasma tau levels were highest in the MM/MV type 1 and MM type 1 + 2 subtypes (in the latter group, due to a single sample with a high concentration). The M-W test revealed significantly higher values of plasma and CSF tau levels for most of the molecular subtypes compared to the MV type 2 (kuru plaque) sporadic CJD cases (Fig. 1e, f) . NF-L plasma and CSF levels showed similar patterns, although fewer comparisons were significant (Fig. 1g, h ). In the ROC curve analysis for plasma tau, MM/MV type 1 cases compared to MV type 2K cases showed an AUC of 0.990 (95% CI 0.96-1.0) and 0.874 (95% CI 0.74-1.0) compared to VV type 2 cases. Importantly, the lower tau and NF-L levels in MV type 2K cases were still higher compared to non-diseased controls (M-W test: CSF tau, CSF and plasma NF-L, P < 0.001; plasma tau, P = 0.1); however, plasma tau and NF-L levels were not significantly different in AD and MV type 2K sporadic CJD cases. Finally, in genetic CJD, only weak effects of the codon 129 could be seen (low case numbers). Weak significance was observed for the comparison of plasma tau (M-W; P = 0.04) concentrations; this was higher in cases with MM at codon 129 compared to those with MV (n = 7).
Discussion
The identification of proteins related to specific neurodegenerative diseases has opened new avenues for disease classification and biomarker development [1, 33] . Contrasting dementia with Lewy bodies, vascular dementia and frontotemporal dementia for AD and CJD, CSF biomarkers are already available in practice for support of the clinical diagnosis (e.g. total tau, p-tau and Ab for AD or 14-3-3 for CJD) [34] . Whilst there are efforts to detect disease-associated Figure 1 Scatter plots of plasma tau (a, e), NF-L (c, g) and CSF tau (b, f) and NF-L (d, h) (units pg/ml) in all disease groups examined (a-d) and in molecular subtypes of sporadic CJD (e-h). Horizontal lines in each plot for each disease group indicate the mean value observed for that group. The horizontal line spanning the whole graph area in e-h represents the mean values for the total cohort of sporadic CJD. *P < 0.05; **P < 0.01; ***P < 0.001. OND, other neurological disorder; AD, Alzheimer disease; sCJD, sporadic Creutzfeldt-Jakob disease; gCJD, genetic CJD; CO, healthy controls.
protein modifications in the blood [2, 35, 36] , markers that reflect neuronal degeneration may be more tangible. In particular, these might be used to predict prognosis, clinical outcome [37] and eventually response to disease-modifying drugs targeting the underlying pathophysiologies or neuroprotective therapies. However, these indicators show much lower levels in blood samples compared to CSF, and highly sensitive immunochemical methods for their detection are needed. Importantly, recent studies have reported that tau and NF-L can be detected in blood [20] [21] [22] [23] [24] 31, 32, 37] . To be able to define the reliability of these tests, different diseases and their combinations need to be examined. This was precisely the aim in this study and therefore cases with detailed neuropathological analysis were included.
First it is shown that both tau and NF-L levels measured in the plasma correlate with the levels measured in CSF but, as expected, are found in much lower concentrations. The sensitivity and specificity of the blood tests are comparable to those of the CSF, which is important since both are widely accepted markers of neuronal damage due to various aetiologies. Significant correlation of tau with NF-L levels is demonstrated both in plasma and CSF. Combined evaluation of tau and NF-L can be used as confirmatory examinations. This is important since a recent meta-analysis demonstrated that the core CSF biomarkers of neurodegeneration (total tau, p-tau and Ab42), together with CSF NF-L, are strongly associated with AD [38] . The recently reported high sensitivity and specificity of NF-L and tau levels in the plasma and CSF for CJD compared to non-diseased controls are confirmed [39] . However, the AUCs are lower when CJD groups are compared to other disease groups. In the latter comparisons disease groups contained a pool of individual cases with various molecular subtypes (i.e. sporadic CJD) or combined pathologies (i.e. AD with or without vascular lesions). Therefore, on an individual level both tau and NF-L may be suitable to support the diagnosis of a disorder with considerable neuronal damage; however, further neuroimaging or CSF tests are still needed for disease classification.
One major focus of our analyses was CJD. Human prion diseases belong to the most dramatic neurodegenerative disorders with rapid and prominent neuronal loss. However, these show different disease courses based on molecular characteristics, which can be defined with the examination of the PRNP gene together with brain tissue, usually postmortem [14] . Our observations in plasma support the importance of total tau levels [11] to distinguish CJD from controls but also from AD or other disorders with neuronal damage. In concordance with other reports [3, 13] , it is shown, however, that the molecular subtypes of sporadic CJD might be associated with different levels of total tau and NF-L. This is compatible with the observations of longer duration of illness, for example in MV type 2 cases [14] . Indeed, sporadic CJD subtypes are both qualitatively and regionally distinct in the predominance of neuronal death markers, confirming regional vulnerabilities of sporadic CJD subtypes that potentially reflect distinct responses to pathogenic events [40] . Interestingly, the lowest tau and NF-L levels were detected in a patient with variably protease-sensitive prionopathy (VPSPr) treated with doxycycline and showing nearly 5 years' duration of illness [41] . VPSPr is a neurodegenerative disorder with spongiform encephalopathy and an unusual immunostaining and immunoblotting pattern for the disease-associated PrP with long duration of disease [42] . It is shown that the time interval between sampling and death correlates inversely with plasma tau levels and less with NF-L. Currently, in AD-related cognitive decline several studies indicate that the CSF level of tau [43, 44] , as well as the CSF Ab42/p-tau ratio [45] , can serve as a predictor of clinical progression. Therefore, plasma tau level could be discussed also as a potential prognostic factor in both AD and CJD. As a limitation of our study a precise correlation of the state of neurodegeneration at the time of sampling cannot be provided. In particular, our cohort included various disorders, including molecular subtypes, whilst for homogeneous disease groups NF-L levels can also be used to predict clinical outcome [37] .
In our cohort, the Braak stage of neurofibrillary degeneration or Lewy body pathology did not show a strong effect on the tau levels. However, it must be noted that a low number of pure AD and dementia with Lewy bodies cases were included and the effect of additional pathologies limits an exact evaluation. This is not contrary to findings in AD that cognitive impairment seems to correlate best with the burden of neocortical neurofibrillary tangles [46] , but rather suggests that tau and NF-L levels (i.e. plasma and CSF) reflect a relatively constant progression level of neuronal damage in AD. Higher values can be related to additional neuronal damage such as vascular lesions. In the context of dementia, AD and vascular dementia associate with medium to strong increase whilst CJD associates with a very strong increase of total tau concentration [47] . In the current practice of dementia diagnosis only a small proportion of patients undergo CSF examination. Since plasma concentrations perform similarly to CSF, plasma testing of tau and NF-L can be used as an early screening for suspected neuronal damage and can be offered to more patients. As a cautionary note, our study indicates that inflammation, especially associated with prominent neuronal damage or hypoxic/ischaemic brain damage, also associates with higher NF-L and tau levels. Usually, these disorders do not pose differential diagnostic issues for CJD or AD (i.e. increased cell counts and clinical course). Our cohort was based on the routine diagnostic practice of evaluating patients with rapidly progressive neurological syndromes. In this sense our observations further support the prognostic value of tau and NF-L in various disorders with neuronal damage but do not allow specification of the diagnosis, although the degree of elevation of NF-L and tau levels can be helpful to predict the onset [39] or to raise the suspicion of prion disease. When these tests are used in the frame of dementia evaluation, however, plasma tau and NF-L concentrations can be rapid and useful tests to raise the suspicion of neuronal damage or degeneration, contrasting patients with subjective cognitive decline, depression or metabolic causes.
Conclusion
Our neuropathology-based study shows that plasma tau and NF-L levels reflect those in CSF and may be used to substitute them in, for example, studies where CSF sampling is not feasible. It is shown that the highest levels of tau can be detected in CJD; however, rare molecular subtypes may show lower levels. Thus, a combined evaluation of the polymorphic codon 129 of the PRNP can be helpful to interpret these results. Increased levels of tau and NF-L in AD are demonstrated compared to controls. Unexpected higher levels can be observed in additional vascular lesions or inflammatory changes associated with neuronal damage. It is known that the evaluation of plasma tau and NF-L levels alone will be insufficient to specifically diagnose a disease; however, due to the practicability of blood tests, and their strong association with tissue lesioning, they can reliably support clinical practice for evaluating the degree and dynamics of neuronal damage, also for example in the context of dementia screening. Finally, an extreme elevation of plasma tau, together with a constellation of clinical symptoms, might support the suspicion of human prion disease.
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